Galapagos NV (AMS:GLPG)
Netherlands · Delayed Price · Currency is EUR 24.60
-0.06 (-0.24%)
Apr 15, 2026, 5:35 PM CET
Galapagos NV Company Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The company’s pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Galapagos NV
| Country | Belgium |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 558 |
| CEO | Henry Gosebruch |
Contact Details
Address: Generaal De Wittelaan L11 A3 Mechelen, 2800 Belgium | |
| Phone | 32 1 534 29 00 |
| Website | glpg.com |
Stock Details
| Ticker Symbol | GLPG |
| Exchange | Euronext Amsterdam |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0003818359 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Henry Gosebruch | Chief Executive Officer and Executive Director |
| Aaron L. Cox | Chief Financial Officer |
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Head of Investor Relations |
| Fred W. Blakeslee II | Executive Vice President and General Counsel |
| Marieke Vermeersch | Head of Corporate Communication |
| Tania Philipp | Chief Human Resources Officer |
| Ellen Van Der Aar | Head of Development |
| Annelies Missotten | Executive Officer |
| Dr. Jeevan Shetty | Head of Clinical Development Oncology |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy |